Comparison of the effect of direct-acting antiviral with and without ribavirin on cyclosporine and tacrolimus clearance values: results from the ANRS CO23 CUPILT cohort
ConclusionOur study demonstrated that liver transplant patients with a recurrence of hepatitis C who are initiating ribavirin combined with a sofosbuvir-daclatasvir direct-acting antiviral regimen may be at risk of lower tacrolimus concentrations because of probable ribavirin-induced anaemia and higher fibrosis score, although there are no effects on cyclosporine levels.Trial registrationNCT 01944527
Source: European Journal of Clinical Pharmacology - Category: Drugs & Pharmacology Source Type: research
More News: Anemia | Drugs & Pharmacology | Hepatitis | Hepatitis C | Liver | Liver Transplant | Prograf | Restasis | Study | Tacrolimus | Transplant Surgery | Transplants | Urology & Nephrology